From: http://www.4cmed.com/technology
"Our initial focus is to develop a novel therapy for mitral regurgitation (MR), and subsequently for tricuspid regurgitation (TR)."
I would assume adapt process tissue will be used in any subsequent developments too. Especially given there was an article published recently which concluded that CardioCel was suitable in this application. (Amongst others I would imagine)
https://www.ncbi.nlm.nih.gov/pubmed/28838511
Ann: Exclusive Supply Agreement with 4C Medical, page-16
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.19 |
Change
-0.010(0.08%) |
Mkt cap ! $257.6M | |||
| Open | High | Low | Value | Volume |
| $12.19 | $12.20 | $11.60 | $173.1K | 14.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9 | $11.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.19 | 28 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |